The polymorphic inheritance of DIO2 rs225014 may predict body weight variation after Graves’ disease treatment

Abstract

Objective: We aimed to investigate the role of DIO2 polymorphisms rs225014 and rs12885300 in Graves' disease patients, mainly for controlling body weight following treatment. Subjects and methods: We genotyped 280 GD patients by the time of diagnosis and 297 healthy control individuals using a TaqMan SNP Genotyping technique. We followed up 141 patients for 18.94 ± 6.59 months after treatment. Results: There was no relationship between the investigated polymorphisms with susceptibility to GD and gain or loss of weight after GD treatment. However, the polymorphic inheritance (CC+CT genotype) of DIO2 rs225014 was associated with a lower body weight variation after GD treatment (4.26 ± 6.25 kg) when compared to wild type TT genotype (6.34 ± 7.26 kg; p = 0.0456 adjusted for the follow-up time). This data was confirmed by a multivariate analysis (p = 0.0138) along with a longer follow-up period (p = 0.0228), older age (p = 0.0306), treatment with radioiodine (p-value = 0.0080) and polymorphic inheritance of DIO2 rs12885300 (p = 0.0306). Conclusion: We suggest that DIO2 rs225014 genotyping may have an auxiliary role in predicting the post-treatment weight behavior of GD patients.

Current Understanding of Human Polymorphism in Selenoprotein Genes: A Review of Its Significance as a Risk Biomarker

“…The TT genotype was associated with a better outcome one year after acute ischemic stroke than one minor G allele in Lithuania patients [110]. Some studies could not find an association between the polymorphisms and certain diseases: Thr92Ala polymorphism and the severity of obesity after bariatric surgery in Italy [112], Thr92Ala polymorphism and cognitive impairment in older adults in Brazil [113], rs12885300 polymorphism and the body weight variation after Graves' disease treatment in Brazil [109], and rs12095080, rs11206244, rs2235544 polymorphisms in DIO 1 and rs225014 and rs225015 in DIO2 with acute ischemic stroke outcome [110].…”

The Physiological Functions and Polymorphisms of Type II Deiodinase

“…In patients with total thyroidectomy treated with LT4, heterozygous and rare homozygous patients carrying the Thr92Ala polymorphism in the DIO2 gene showed reduced free triiodothyronine (FT3) levels when data were analyzed assuming both dominant and recessive models, indicating that Thr92Ala- DIO2 might inhibit the conversion from T4 to T3 by DIO2 [ 91 ]. In Graves’ disease (GD) patients, the polymorphic inheritance (CC+CT genotype) of DIO2 rs225014 was associated with less body weight variation after GD treatment than in patients with the wild-type TT genotype, suggesting that DIO2 rs225014 genotyping might have an auxiliary role in predicting the posttreatment weight behavior of GD patients [ 92 ]. de Lima Beltrao et al [ 93 ] investigated a possible association between the Thr92Ala- DIO2 polymorphism and in-hospital mortality from COVID-19 in adult patients admitted between June and August 2020, and the results showed lower lethality in people with the heterozygous genotype (Thr/Ala) than in those with homozygous genotypes (Thr/Thr and Ala/Ala), implying a protective role of Thr92Ala- DIO2 heterozygosity.…”